Answers are grounded in this paper and cite their sources.
Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs have, high-dose regimens that trigger efficacy are explored. Here, we studied unprecedented drug exposure-response relationships in vitro using mCRC patient-derived tumour organoids (PDTOs).
No takes yet. Share an insight, caveat, or question.
Iyer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: